GeneDx Holdings Corp.

GeneDx Holdings Corp., listed under the ticker CMLF, filed an 8-K with the Securities and Exchange Commission on June 24, 2024. The company originated as CM Life Sciences III Inc., a life-sciences-focused special purpose acquisition company that completed its initial public offering in 2021 under sponsorship from CM Life Sciences LLC, an affiliate of Casdin Capital. Following its business combination with Sema4 Holdings Corp., the entity rebranded as GeneDx Holdings Corp. after acquiring GeneDx, a genomic diagnostic testing business previously owned by OPKO Health. The company now operates in the precision medicine and genomics sector as a post-combination, publicly traded diagnostics firm. Sign up for SpacDesk to access full filing histories, deal timelines, and analytics on GeneDx Holdings and hundreds of other SPAC transactions.